Aristopharma Ltd. is pleased to introduce Asmalin Plus, a Salbutamol + Budesonide HFA inhaler and the first US FDA-approved combination rescue medication for Asthma attacks.
Asmalin Plus HFA Inhaler is a combination of salbutamol (a beta2-adrenergic agonist) and budesonide (a corticosteroid), indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma. Salbutamol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles, while budesonide has a wide range of inhibitory activities against multiple cell types and mediators involved in inflammation.
FR
DE